ClinicalTrials.gg
RecruitingNCT05899920SAGAUpdated Apr 24, 2024

Clinical One-stage Controlled Study of reSistant Arterial Hypertension for the desiGning of a personAlized Approach to Therapy

An interventional study of Blood samples will be taken for pharmacokinetics and pharmacogenetics in Resistant Arterial Hypertension, sponsored by Ryazan State Medical University. Recruiting at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-24.

Sponsored by Ryazan State Medical University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as recruiting.
  • Registered 1 year 1 month after the study started (first participant enrolled Mar 2022, registered May 2023).
  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 88 studies in Hypertension with a site in Russian Federation — 6 open to participants now, 7 under way, none of them phase 3. Hypertension · Russian Federation.

Planned enrollment
36th of 60
190 · median 348
Started
2022
the only one that year
No phase
8 of 88
3 open now
Registered
82nd of 88
by date

Among the 88 studies in Hypertension with a site in Russian Federation, this one is the 36th largest by planned enrollment of the 60 interventional ones that give a count, is the only one that started in 2022, is one of 8 with no phase, and was the 82nd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 88 studies in Hypertension with a site in Russian Federation are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Hypertension with a site in Russian Federation, or all of them as a file.
02

Study summary

This study was planned to assess the concentration of antihypertensive drugs in the blood plasma in patients with controlled and uncontrolled arterial hypertension. Methods: it is planned to include patients with arterial hypertension taking 3 antihypertensive drugs (indapanide, lisinopril or valsartan, amlodipine). Based on the results of 24-hour blood pressure monitoring, the patients will be randomized into two groups: The first group - the patients with controlled AH; The second group - the patients with uncontrolled AH. Venous blood was taken in both groups of the patients in the morning before and 2 hours after taking drugs to assess the concentration of lisinopril, amlodipine, valsartan and indapamide. Concentation of assesed antihypertensive drugs will be compared in both groups.

03

Conditions studied

  • Resistant Arterial Hypertension

Browse trials for

Keywords

  • antihypertensive drugs
  • concentration
  • HPLC MS/MS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form;
  • An established diagnosis of AH based on the Clinical Guidelines "Arterial hyperten-sion in adults", approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation, 2020;
  • Mandatory patient compliance with recommendations for lifestyle modification in accordance with the Clinical Guidelines "Arterial hypertension in adults", approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation, 2020 .
  • Regular administration of any two antihypertensive drugs (lisinopril, amlodipine, valsartan) in combination with indapamide for a month, possibly in fixed combinations, in stable dosages;
  • Fertile female patients must use proper methods of throughout the study period.

Exclusion criteria

Exclusion Criteria:

  • Patient's connection with the organization or conducting of the study;
  • Pregnancy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
190 participants (estimated)

Study arms

  • Active comparator
    Controlled arterial hypertension

    Controlled arterial hypertension according the results of 24-hour blood pressure monitoring. Blood samples will be taken for pharmacokinetics and pharmacogenetics

    Diagnostic Test: Blood samples will be taken for pharmacokinetics and pharmacogenetics

  • Experimental
    Uncontrolled arterial hypertension

    Uncontrolled arterial hypertension according the results of 24-hour blood pressure monitoring. Blood samples will be taken for pharmacokinetics and pharmacogenetics

    Diagnostic Test: Blood samples will be taken for pharmacokinetics and pharmacogenetics

Interventions

  • Diagnostic testBlood samples will be taken for pharmacokinetics and pharmacogenetics

    To assess antihypertensive drugs concentration (lisinopril, valsartan, amlodipine, indapamide

06

What researchers measure

Primary outcomes

  1. Plasma Concentration of lisinopril, valsartan, amlodipin, indapamide, metoprolol

    Number of Participants with antihypertensive drug concentraion below the limit of quantitative determination

    Time frame: day 1

07

Study locations

1 of 1 sites recruiting
  • Ryzan State Medical University
    Ryazan, 390026, Russian Federation
    Recruiting
    • Sergey V Seleznev, MD, PhD · Contactsv.seleznev@gmail.com · +79105749526
    • Alexey V Shchulkin, MD, PhD · Contactalekseyshulkin@rambler.ru · +79209520024
    • Sergey S Yakushin, MD, PhD · Principal investigator
    • Pavel Yu Mylnikov, MD, PhD · Sub investigator
    • Elena N Yakusheva, MD, PhD · Sub investigator
    • Natalia N Nikulina, MD, PhD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Nov 2024, 32 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 32 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2023
First posted
Jun 12, 2023
StartActual
Mar 11, 2022
Primary completionEst.
Nov 11, 2024
CompletionEst.
Dec 31, 2024
Last update
Apr 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05899920
Lead sponsor
Ryazan State Medical University
Responsible party
Sponsor
First posted
Jun 12, 2023
Start date
Mar 11, 2022
Primary completion
Nov 11, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Apr 24, 2024

Study contacts

Sergey V Seleznev, MD, PhD
Contact
sv.seleznev@gmail.com
+79105749526
Alexey V Shchulkin, MD, PhD
Contact
alekseyshulkin@rambler.ru
+79209520024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion